Create Free Account

By creating account you will get access to hot stocks & personalised emails

Lumos Diagnostics Holdings Ltd

Healthcare AU LDX

0.031AUD
0.001(3.33%)

Last update at 2025-02-05T04:44:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.030.09
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap29.94M
  • Volume814443
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.97200M
  • Revenue TTM11.13M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 6.56M
  • Diluted EPS TTM-0.03

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -8.97100M -45.72400M -20.12700M -13.53320M -7.41649M
Minority interest - - - - -
Net income -8.97100M -45.72400M -20.12700M -13.44704M -6.54585M
Selling general administrative 10.22M 16.86M 22.21M 16.40M 6.28M
Selling and marketing expenses - 2.27M - - -
Gross profit 5.97M 4.46M 11.52M 3.64M 2.90M
Reconciled depreciation 3.67M 2.82M - - -
Ebit -10.23600M -21.49400M -11.00200M -15.53300M -4.11323M
Ebitda -4.92900M -18.67100M - - -
Depreciation and amortization - 2.82M - - -
Non operating income net other - - - - -
Operating income -9.52700M -21.49400M -14.56600M -12.79737M -7.26794M
Other operating expenses - 32.70M 0.66M 0.66M 0.08M
Interest expense 0.37M 0.17M 0.00000M 0.02M 0.02M
Tax provision 0.00000M 0.00000M 0.00000M -0.08616M -0.87064M
Interest income 0.02M 0.61M 3.02M 0.74M 0.15M
Net interest income -0.79100M -0.61000M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.19M - -0.08600M -0.87064M
Total revenue 10.54M 11.63M 25.05M 8.40M 6.38M
Total operating expenses - 25.53M - - -
Cost of revenue 4.56M 7.17M 13.53M 4.76M 3.48M
Total other income expense net 1.35M -24.04100M - - -
Discontinued operations - - - - -
Net income from continuing ops -8.97100M -45.72400M - - -
Net income applicable to common shares -8.97100M -45.72400M -15.03000M -13.44700M -6.54585M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 26.84M 25.42M 36.94M 130.55M 43.87M
Intangible assets 9.69M 10.89M 12.53M 32.91M 29.89M
Earning assets - - - - -
Other current assets 1.01M - 1.05M - 0.03M
Total liab 19.73M 15.92M 19.05M 52.82M 11.77M
Total stockholder equity 7.11M 9.50M 17.89M 77.73M 32.10M
Deferred long term liab - 7.19M 8.15M 8.76M 8.75M
Other current liab 12.08M 3.46M 10.41M 25.21M 1.90M
Common stock 98.23M 92.47M 92.14M 84.22M 23.13M
Capital stock - 92.47M 92.14M - -
Retained earnings -90.86000M -82.29200M -74.53400M -28.81000M -20.03700M
Other liab - - - - -
Good will - - 0.00000M 1.47M 1.47M
Other assets - 7.19M 8.15M 8.76M 8.83M
Cash 6.48M 3.02M 7.98M - 1.23M
Cash and equivalents - - 7.98M 44.89M 0.85M
Total current liabilities 12.62M 8.17M 12.83M 32.51M 7.07M
Current deferred revenue - - 3.75M - -
Net debt -6.47900M - -0.78400M - -
Short term debt - - 0.97M 0.00000M 0.00000M
Short long term debt - 1.35M - - -
Short long term debt total - - 7.19M - 4.70M
Other stockholder equity - -0.67800M 0.28M 2.87M 1.46M
Property plant equipment - 8.56M 10.97M 14.88M 6.84M
Total current assets 9.56M 5.96M 13.44M 57.06M 5.31M
Long term investments - - - - -
Net tangible assets - 5.80M 13.50M 41.20M -18.06300M
Short term investments - - - - -
Net receivables 0.67M 1.49M 1.89M 4.25M 1.35M
Long term debt - - - - -
Inventory 0.78M 1.06M 2.53M 4.44M 0.73M
Accounts payable 0.55M 1.14M 1.45M 4.56M 3.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.25900M - 0.28M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 17.28M 19.45M 23.50M - -
Capital lease obligations - 8.44M 7.19M - -
Long term debt total - - 6.23M 9.57M 3.24M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 4.31M -4.35500M - - -0.27056M
Change to liabilities -6.17800M -3.09500M 8.33M 0.67M 2.68M
Total cashflows from investing activities 4.31M -4.35500M -8.33200M -9.44600M -11.72585M
Net borrowings 0.79M -1.20600M 16.26M -0.23600M 19.99M
Total cash from financing activities 0.65M -10.91900M 63.27M 11.76M 19.99M
Change to operating activities 0.50M 1.54M -0.47900M 0.22M -1.14586M
Net income -8.97100M -45.72400M -15.03000M -13.44700M -6.54585M
Change in cash -4.96300M -36.91200M 44.04M -3.13900M 4.04M
Begin period cash flow 7.98M 44.89M - - -
End period cash flow 3.02M 7.98M 44.89M - -
Total cash from operating activities -9.63800M -18.03600M -10.88900M -5.44500M -4.32259M
Issuance of capital stock - 7.87M - - -
Depreciation 3.03M 2.42M 0.45M 0.58M 0.18M
Other cashflows from investing activities - - - - -8.12457M
Dividends paid - - - - -
Change to inventory 0.81M -1.35400M -3.93900M -0.71800M -0.05990M
Change to account receivables 0.93M -0.18000M -3.32600M 0.60M -1.63662M
Sale purchase of stock - -9.71300M 57.81M 12.00M -
Other cashflows from financing activities -0.13400M -18.78900M 17.58M 17.58M 17.58M
Change to netincome -0.73700M 27.95M 3.01M 6.44M 1.71M
Capital expenditures 0.12M 4.36M 5.88M 9.45M 3.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - 0.02M 0.00600M 2.72M -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -9.79300M -4.35500M - - -

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LDX
Lumos Diagnostics Holdings Ltd		 0.001 3.33% 0.03 - - 2.69 2.64 1.83 -0.3297
COH
Cochlear Ltd		 -1.05 0.34% 311.40 58.68 49.51 9.33 11.23 9.13 35.24
PNV
Polynovo Ltd		 -0.015 0.76% 1.95 209.00 140.85 13.99 20.40 13.96 356.05
EBR
Ebr Systems Inc CDR		 -0.065 3.62% 1.73 - - - 13.02 - -3.6785
AVH
Avita Therapeutics Inc		 0.08 2.79% 2.95 - - 6.55 20.55 4.18 -10.0538

Reports Covered

Stock Research & News

View All

Profile

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers. The company was incorporated in 2018 and is based in Carlsbad, California.

Lumos Diagnostics Holdings Ltd

2724 Loker Ave West, Carlsbad, CA, United States, 92010

Key Executives

Name Title Year Born
Mr. Samuel Lanyon Exec. Chairman NA
Mr. Douglas Ward Chief Exec. Officer NA
Mr. Barrie Lambert Chief Financial Officer NA
Dr. Sacha Dopheide Ph.D. Chief Technology Officer NA
Ms. Jennifer Christiansen VP of Corp. Marketing & Communications NA
Ms. Sarah Glubka Sr. Director of HR NA
Ms. Annie Bell Sr. Director of Medical Affairs NA
Ms. Sue Hibbeln Sr. Director of Regulatory Affairs NA
Mr. Paul Kase Sr. VP of Commercial Operations NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Company Sec. 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

Market Research
ISO Certified pcidss

Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2404072) and the PCI-DSS Version 4.0 Level 1 certification (Certificate No. CSNL1PCI8067).

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.